Lantus up last week, but new scrips fall

In the wake of new safety concerns about the drug, total U.S. prescription volume for the Sanofi-Aventis diabetes drug Lantus inched up 2 percent last week versus the week before, but new prescriptions were down 3.8 percent, according to a drug-data provider. Report

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.